172 related articles for article (PubMed ID: 10087005)
1. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
Du F; Li R; Huang Y; Li X; Le W
Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
Carvey PM; Pieri S; Ling ZD
J Neural Transm (Vienna); 1997; 104(2-3):209-28. PubMed ID: 9203083
[TBL] [Abstract][Full Text] [Related]
4. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Presgraves SP; Borwege S; Millan MJ; Joyce JN
Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
Takashima H; Tsujihata M; Kishikawa M; Freed WJ
Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
Collo G; Zanetti S; Missale C; Spano P
Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
[TBL] [Abstract][Full Text] [Related]
8. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures.
Ling ZD; Tong CW; Carvey PM
Brain Res; 1998 Apr; 791(1-2):137-45. PubMed ID: 9593863
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
10. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
11. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
12. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
[TBL] [Abstract][Full Text] [Related]
13. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
[TBL] [Abstract][Full Text] [Related]
14. D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins.
Liu LX; Burgess LH; Gonzalez AM; Sibley DR; Chiodo LA
Synapse; 1999 Feb; 31(2):108-18. PubMed ID: 10024007
[TBL] [Abstract][Full Text] [Related]
15. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
Malik P; Andersen MB; Peacock L
Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
[TBL] [Abstract][Full Text] [Related]
16. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype.
Merlo S; Canonico PL; Sortino MA
Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591
[TBL] [Abstract][Full Text] [Related]
17. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist.
Camacho-Ochoa M; Walker EL; Evans DL; Piercey MF
Neurosci Lett; 1995 Aug; 196(1-2):97-100. PubMed ID: 7501268
[TBL] [Abstract][Full Text] [Related]
18. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
